Corvus Pharmaceuticals, Inc. (CRVS)
After hours:
| Previous close | 5.13 |
| Open | 5.20 |
| Bid | 5.08 x 500 |
| Ask | 5.15 x 400 |
| Day's range | 4.96 - 5.22 |
| 52-week range | 1.05 - 5.22 |
| Volume | |
| Avg. volume | 319,893 |
| Market cap | 319.012M |
| Beta (5Y monthly) | 1.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.43 |
| Earnings date | 05 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.88 |
ZacksCorvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
GlobeNewswireCorvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical
- GlobeNewswire
Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024. The Company’s presenta
